A Multicenter, Double-Blind, Controlled Study to Evaluate Ampligen
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
To evaluate ampligen at two dosage levels given twice weekly in combination with zidovudine
(AZT) versus AZT alone in individuals with HIV-related immune dysfunction defined as T4 count
between 100 and 300 cells/mm3.